Most Read Articles
12 Jun 2019
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
2 days ago
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 13 Jun 2019

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

13 Jun 2019
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.

Not all NSAIDs are created equal: Assessing the cardiovascular safety of COX-2 selective NSAIDs

01 Feb 2019
The significant cardiovascular-related mortality pattern can enhance understanding of the relevant factors within certain geographical regions.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat osteoarthritis and rheumatoid arthritis to reduce joint pain and improve joint function. Dr Sazzli Kasim provides his viewpoint on how the current understanding on cardiovascular safety of NSAIDs should be taken into account when determining optimal analgesic strategies for patients with arthritis.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2019
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
2 days ago
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 13 Jun 2019

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

13 Jun 2019
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.